FRENCH HEALTH CARE SPENDING FORECASTS

13 December 1993

Around 10,000 French health care professionals - health fund administrators, doctors, hospital staff and drug companies - believe that health spending will continue to rise to 1998, and that the social security system will reimburse less and less of this spending, says a study conducted by Andersen Consulting. Parallel with the reimbursement cuts will be the expansion of complementary insurance arrangements, said those polled.

The survey concludes that French health care will go through five major phases before 1998. First, costs will go on rising, though the survey reported differing views on the government's ability to control costs. The best guesstimate is that spending will grow 0.5% to 2% of Gross Domestic Product, faster than in other European countries. This will reflect the aging population, the AIDS epidemic, the development of medical technology, medical demography and the more complex character of medicine.

Second, the element of solidarity on which the health insurance system is based will weaken. Increased fund premiums will be accepted with growing reluctance, social regimens will reduce their cover and the sick will have to pay a larger share of their costs. Some 45% of those polled said the social security system would keep its monopoly but 48% felt it would have to compete with private organizations. Third, the authorities would have a growing role in health service organization, and while out-patient general practitioner treatment would increase its share of health spending, hospital spending would fall as a proportion of total spending.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight